Drug Guide

Generic Name

Fluticasone Furoate

Brand Names Flonase Sensimist Allergy Relief, Arnuity Ellipta

Classification

Therapeutic: Allergic rhinitis, Asthma

Pharmacological: Inhaled corticosteroid

FDA Approved Indications

  • Relief of symptoms of allergic rhinitis (nasal congestion, sneezing, rhinorrhea, nasal itching)
  • Maintenance treatment of asthma in adults and adolescents

Mechanism of Action

Fluticasone Furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple types of inflammatory cells, decreasing edema of nasal mucosa, and reducing the release of mediators involved in allergic reactions.

Dosage and Administration

Adult: For allergic rhinitis: 2 sprays in each nostril once daily. For asthma: 100 mcg once daily for adults.

Pediatric: For asthma: 100 mcg once daily in adolescents aged 12 and over.

Geriatric: Dose adjustments are generally not necessary but should be individualized based on response.

Renal Impairment: No specific adjustments needed.

Hepatic Impairment: No specific adjustments recommended.

Pharmacokinetics

Absorption: Minimal nasal absorption; systemic absorption occurs and varies based on dose.

Distribution: Wide distribution after absorption; protein binding is approximately 90%.

Metabolism: Primarily hepatic via CYP3A4.

Excretion: Metabolites are excreted mainly in urine and feces.

Half Life: Approximately 15 hours.

Contraindications

  • Hypersensitivity to fluticasone or any component of the formulation.

Precautions

  • Use with caution in patients with active or untreated infections of the nasal mucosa. Avoid contact with eyes to prevent glaucoma or cataracts.
  • Use during active infection of the nasal mucosa should be cautious.

Adverse Reactions - Common

  • Headache (Common)
  • Nasal irritation or burning (Common)
  • Pharyngeal pain (Common)
  • Cough (Common)

Adverse Reactions - Serious

  • Glaucoma or cataracts (Rare)
  • Systemic corticosteroid effects (adrenal suppression, osteoporosis, etc.) (Rare)

Drug-Drug Interactions

  • Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic corticosteroid risk.

Drug-Food Interactions

  • None significant

Drug-Herb Interactions

  • None well-established

Nursing Implications

Assessment: Monitor nasal symptoms and control of asthma. Assess for signs of systemic corticosteroid effects.

Diagnoses:

  • Risk for infection
  • Ineffective airway clearance

Implementation: Administer as prescribed. Educate patient on proper nasal spray technique.

Evaluation: Symptom relief, minimal adverse effects, and no signs of systemic corticosteroid effects.

Patient/Family Teaching

  • Use nasal spray as directed, do not exceed prescribed dose.
  • Report any signs of nasal irritation, vision changes, or mood changes.
  • Do not stop medication abruptly.
  • Use regularly for best results.

Special Considerations

Black Box Warnings:

  • Oral corticosteroids may cause significant side effects; inhaled forms have lower risk but systemic absorption can occur.

Genetic Factors: No specific genetic considerations.

Lab Test Interference: None significant.

Overdose Management

Signs/Symptoms: Potential systemic corticosteroid effects such as adrenal suppression, hyperglycemia, or Cushingoid features if taken in excess.

Treatment: Supportive care; consider corticosteroid tapering if systemic effects are evident.

Storage and Handling

Storage: Store at room temperature, 20-25°C (68-77°F).

Stability: Stable until expiration date on packaging.

This guide is for educational purposes only and is not intended for clinical use.